• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»androgenetic alopecia

Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data

By Pallavi Madhiraju on May 10, 2026   Medical Devices & Diagnostics  

Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data

Aesthetics needs stronger evidence. Lumenis is using ASLMS data to push lasers deeper into hair loss, skin and rhinophyma care.

Why the Veradermics hair loss trial is bigger than another aesthetics readout

By Pallavi Madhiraju on April 27, 2026   Pharma & Biotech  

Why the Veradermics hair loss trial is bigger than another aesthetics readout

Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.

Menopause-specific hair loss enters the clinical spotlight after KilgourMD trial data

By Pallavi Madhiraju on February 20, 2026   Pharma & Biotech  

Menopause-specific hair loss enters the clinical spotlight after KilgourMD trial data

KilgourMD’s phase II data challenges how menopause-related hair loss is studied and treated. See what changes and what clinicians will watch next.

Will Veradermics’ non-hormonal oral pill become the first FDA-approved hair loss therapy in decades?

By Srinath B on December 11, 2025   Pharma & Biotech  

Will Veradermics’ non-hormonal oral pill become the first FDA-approved hair loss therapy in decades?

Veradermics just completed pivotal trial enrollment for VDPHL01, its oral minoxidil for hair loss. Will it reshape dermatology? See what’s next.

Recent Posts

  • Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes